Physician profile
Jennifer E Muraski
NPI 1467774646
$594.86
in general payments reported to CMS, 2019-2025
15 companies · $18.99 in 2025
The $18.99 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $178 · 2023: $75.30 · 2024: $99.38 · 2025: $18.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $145.16 | 2021-2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $114.92 | 2022-2024 | Jornay Pm |
| Corium, LLC | $57.31 | 2022 | |
| Eisai INC. | $56.84 | 2021 | |
| Greenwich Biosciences, INC. | $33.27 | 2021 | |
| Supernus Pharmaceuticals, INC. | $32.90 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $23.04 | 2021 | |
| Pfizer INC. | $21.21 | 2024 | |
| Collegium Pharmaceutical, INC. | $18.99 | 2025 | Jornay Pm |
| Novo Nordisk INC | $18.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.21 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.36 | 2021 | |
| Tris Pharma INC | $17.15 | 2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $14.39 | 2021 | |
| Genentech USA, INC. | $5.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Muraski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.